Differences in Clinical Presentation of Eosinophilic Esophagitis in Pediatric Patients With Ulcerative Colitis and Crohn Disease.
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
pubmed:
21
4
2022
medline:
30
6
2022
entrez:
20
4
2022
Statut:
ppublish
Résumé
Eosinophilic esophagitis (EoE) is an inflammatory condition characterized by T helper-2 (T H 2) cytokines. Ulcerative colitis (UC) and Crohn disease (CD) are inflammatory conditions with different clinical presentations and immune profiles. UC is associated with T H 2 cytokines and CD with T H 1 cytokines. We investigated potential differences in the association of EoE with UC and CD because of these different immune profiles. We utilized ICD-9 and ICD-10 codes to find patients with inflammatory bowel disease (IBD) and EoE. We defined EoE as any esophageal biopsy with >15 eosinophils. We collected demographic, clinical, laboratory, endoscopic, and histological data. Thirty patients had both EoE and IBD. 14.9% of UC patients had EoE and 5.7% of CD patients had EoE. 64.7% of UC patients presented with UC and EoE at the same time, whereas 76.9% of CD patients presented with EoE at follow up. Ten of 13 CD patients were on anti-tumor necrosis factor (TNF) at EoE diagnosis. No UC patients were on anti-TNF at EoE diagnosis. Eighty-three percent of CD patients had mild disease or were in remission, whereas 50% of UC patients had moderate to severe disease at the time of EoE diagnosis. A higher percentage of UC than CD patients had EoE. EoE was more likely to be present at the initial diagnosis of UC than CD. EoE was more likely after diagnosis and treatment of CD with anti-TNF, when CD activity was mild or in remission. The difference in presentation suggests that anti-TNF or it's impact on inflammation may differentially impact the association of EoE with CD and UC.
Identifiants
pubmed: 35442240
doi: 10.1097/MPG.0000000000003460
pii: 00005176-202207000-00015
doi:
Substances chimiques
Cytokines
0
Tumor Necrosis Factor Inhibitors
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
76-80Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR000439
Pays : United States
Informations de copyright
Copyright © 2022 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Furuta GT, Kiacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007;133:1342–63.
Gupta SK, Fitzgerald JF, Kondratyuk T, et al. Cytokine expression in normal and inflamed esophageal mucosa: a study into the pathogenesis of allergic eosinophilic esophagitis. J Pediatr Gastroenteral Nutr. 2006;42:22–6.
Gutierrez-Juquera C, Fernandez-fernandez S, Cilleruelo ML, et al. High prevalence of response to proton pump Inhibitor treatment in children with eosinophilic esophagitis. J Pediatr Gastroenteral Nutr. 2016;62:704–10.
Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease: Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas, ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261–70.
Romangnani S. Basic science review Th1/Th2 cells. Inflamm Bowel Dis. 1999;5:285–94.
Mulder DJ, Hookey LC, Hurlbut DJ. Impact of Crohn’s disease on eosinophilic esophagitis: evidence for an altered Th1–Th2 immune response. J Pediatr Gastroenteral Nutr. 2011;53:213–5.
Pinge Sutto V, Chow C, Turner I. Eosinophilic esophagitis with Crohn’s disease: a new association overlapping immune mediated enteropathy. Am J Gatroenterol. 2009;104:794–95.
Peterson K, Firszt R, Fang J, et al. Risk of autoimmunity in eosinophilic esophagitis and families: a population-based cohort study. Am J Gastroenterol. 2016;111:926–32.
Limketkai BN, Shah SC, Hirano I, et al. Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis. Gut. 2019;68:2152–60.
Moore H, Wechsler J, Frost C, et al. Comorbid diagnosis of eosinophilic esophagitis and inflammatory bowel disease in the pediatric population. J Pediatr Gastroenteral Nutr. 2021;72:398–403.
Sonnenberg A, Turner KO, Gente RM. Comorbid occurrence of Eosinophilic esophagitis and inflammatory bowel disease. Clin Gastroenterol Hepatol. 2021;19:613–5.
Fan YC, Steele D, Kochar B, et al. Increase prevalence of esophageal eosinophilia in patients with inflammatory bowel disease. Inflamm Intest Dis. 2018;3:180–6.
Talathi S, Knight T, Dimmitt R, et al. Concurrent eosinophilic esophagitis in pediatric patients with inflammatory bowel disease. Ann Allergy Asthma Immunol. 2019;123:313–6.
Straumann A, Bussman D, Conus S, et al. Anti-TNF [alpha](infliximab) therapy for severe adult eosinophilic esophagitis. J Allergy Clin Immunol. 2008;122:425–27.
Wenzel SE, Barnes P, Bleecker ER, et al. A randomized, double-blind placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179:549–58.
Guilleminault L, Carre P, Beau-Salinas F, et al. Asthma unmasked with tumor necrosis factor a blocking drugs. Chest. 2011;140:1068–71.
Nigam GB, Bhandare AP, Antoniou GA, et al. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol. 2020;33:346–57.
Sridhar S, Maltz RM, Boyle B, et al. Dermatological manifestations in pediatric patients with inflammatory bowel diseases on anti-TNF therapy. Inflamm Bowel Dis. 2018;24:2086–92.